Agastiya Biotech’s portfolio of novel drug candidates is designed to combat
disease at stem cell and genetic mutation source.
Drugs Designed to Eradicate Cancer at Source
In 2018, Agastiya Biotech took a topical botanical treatment for psroriasis through clinicial trials in India resulting in a first of its kind licensing agreeement with Lupin Pharmaceuticals. Since that time Agastiya Biotech has made rapid breakthroughs in small molecule design and engineering with a focus on cancer therapeutics.
Our pipeline is focused on areas for which the unmet medical need is greatest and for which there are few effective therapies. Our product candidates are at the leading edge of genetic therapies in the industry today.